Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
Stopped early · Phase 1
Conditions studied: Colorectal Cancer, Metastatic Cancer
In brief
RATIONALE: Inserting the interleukin-12 gene into a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-12 gene when injected into the tumors of patients with liver metastases secondary to colorectal cancer.
Key facts
- Study ID
- NCT00072098
- Run by
- Max Sung
- People needed
- 22
- Starts
- 2003-09-01
- Expected to finish
- 2012-01-01
- Last updated by the study team
- 2017-01-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Icahn School of Medicine at Mount Sinai — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.